Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 7, 2002, Pages 2254-2256

  Diallo, Karidia ^a   Oliveira, Maureen ^a   Moisi, Daniela ^a   Brenner, Bluma ^a   Wainberg, Mark A ^a   Götte, Matthias ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESISTANCE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS CULTURE; VIRUS GENE; VIRUS ISOLATION; VIRUS MUTANT; VIRUS REPLICATION; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; HUMAN; MUTATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMAN; LAMIVUDINE; MUTATION; SUPPORT, NON-U.S. GOV'T; VIRUS REPLICATION; ZIDOVUDINE; HUMANS;

EID: 0035984807     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.7.2254-2256.2002     Document Type: Article

References (15)

1. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
2. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors
3. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis
4. Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase
5. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine
6. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
7. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
8. Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study
9. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein
10. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure
11. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: Impact on virological response to efavirenz-based therapy
12. A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β-2′,3′-dideoxy-3′-thiacytidine
13. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
14. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet
15. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA